Diagnosis and management of obstetrical antiphospholipid syndrome: Where do we stand?;Rozpoznawanie i leczenie APS u kobiet w ciazy-aktualny stan wiedzy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 12, 2013, Pages 713-720

  Marchetti, Tess ^a   CohenCohen, Marie ^a   CohenCohenGris, Jean Christophe ^b   De Moerloose, Philippe ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Preeclampsia; Pregnancy; Recurrent miscarriage

Indexed keywords

ADALIMUMAB; AUTOANTIGEN; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE THROMBOCYTOPENIA; CLINICAL FEATURE; ECLAMPSIA; FOLLOW UP; HELLP SYNDROME; HUMAN; IMMUNOMODULATION; PATIENT COUNSELING; PLASMAPHERESIS; PREECLAMPSIA; REVIEW; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENT ABORTION;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84893660964     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2025     Document Type: Review

References (49)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295-306.
2. Costedoat-Chalumeau N, Guettrot-Imbert G, Leguern V, et al. Pregnancy and antiphospholipid syndrome. Rev Med Interne. 2012; 33: 209-216.
3. Danza A, Ruiz-Irastorza G, Khamashta M. Antiphospholpid syndrome in obstetrics. Best Pract Res Clin Obstet Gynaecol. 2012; 26: 65-76.
4. De Groot PG, Meijers JC. B(2)-Glycoprotein I: evolution, structure and function. J Thromb Haemost. 2011; 9: 1275-1284.
5. De Groot PG, Meijers JC, Urbanus RT. Recent developments in our understanding of the antiphospholipid syndrome. Int J Lab Hematol. 2012; 34: 223-231.
6. Barilaro G, Basra G, Murthy V, et al. Antiphospholipid antibody testing update. Successes, challenges, and controversies of diagnostic methods for APS. Rheumatologist. 2012.
7. Boffa MC, Boinot C, De Carolis S, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost. 2009; 102: 25-28.
8. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012; 12: 313-317.
9. De Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009; 7: 1767-1773.
10. Danowski A, Rego J, Kakehasi AM, et al. Guidelines for the treatment of antiphospholipid syndrome. Rev Bras Reumatol. 2013; 53: 184-192.
11. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. 1992; 80: 614-620.
12. Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus. 2013; 22: 6-17.
13. Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistant positive antiphospholipid antibodies and/or lupus anticoagulant in Systemic Lupus Erythematosus. J Rheumatol. 2013; 40: 30-33.
14. Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010; 69: 1827-1830.
15. Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013; 752-757.
16. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study in 1000 patients. Ann Rheum Dis. 2009; 68: 1428-1432.
17. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, et al. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012; 2012: 254319.
18. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med. 1996; 335: 108-114.
19. Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012; 119: 2624-2632.
20. Committee on Practice Bulletins-Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol. 2012; 120: 1514-1521.
21. Francès C, Barete S, Soria A. [Dermatologic manifestations of the antiphospholipid syndrome]. Rev Med Interne. 2012; 33: 200-205.
22. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46: 1019-1027.
23. Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology. 2005; 210: 727-733.
24. Gómez-Puerta JA, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. Clin Lab Med. 2013; 33: 391-400.
25. Hanouna G, Morel N, Le Thi Huong D, et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology (Oxford). 2013; 52: 1635-1641.
26. van den Boogaard E, Hermens RP, Franssen AM, et al. Recurrent miscarriage: do professionals adhere to their guidelines. Hum Reprod. 2013; 28: 2898-2904.
27. Polzin WJ, Kopelman JN, Robinson RD, et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991; 78: 1108-1111.
28. Ruffatti A, Calligaro A, Hoxha A, et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res. 2010; 62: 302-307.
29. Andreoli L, Chighizola CB, Banzato A, et al; on behalf of APS ACTION. The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res (Hoboken). 2013.
30. Buckingham KL, Chamley LW. A critical assessment of the role of antiphospholipid antibodies in infertility. J Reprod Immunol. 2009; 80: 132-145.
31. Rand JH, Wolgast LR. Dos and don'ts in diagnosing antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2012; 2012: 455-459.
32. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006; 33: 2214-2221.
33. Pierangeli SS, Liu XW, Barker JH, et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995; 74: 1361-1367.
34. Murthy V, Willis R, Romay-Penabad Z, et al. Value of isolated IgA anti-β2 GPI positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. 2013.
35. Akhter E, Shums Z, Norman GL, et al. Utility of antiphosphatidylserine/ prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol. 2013; 40: 282-286.
36. Alessandri C, Conti F, Pendolino M, et al. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev. 2011; 10: 609-616.
37. Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev. 2012; 12: 230-234.
38. Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxf). 2013; 52: 1397-1403.
39. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood. 2013. Accepted.
40. Alijotas-Reig J, Ferrer-Oliveras R; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus. 2012; 21: 766-768.
41. Marchetti T, Cohen M, de Moerloose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications. Clin Dev Immunol. 2013; 2013: 159-124.
42. Bank I, Libourel EJ, Middeldorp S, et al. High rate of skin complications due to low-molecular-weight heparins in pregnant women. 2003. J Thromb Haemost, 1: 859-861.
43. Sperber K, Hom C, Peng Chao C, et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatric Rheumatol Online J. 2009; 13: 7-9.
44. Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011; 117: 6948-6951.
45. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
46. Levy RA, Vilela VS, Cataldo M, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10: 401-404.
47. Frassi M, Biasini C, Taglietti M, et al. Hydroxychloroquine in pregnant patients with rheumatic disease: a case control observation of 76 treated pregnancies. Lupus. 2004; 13: 755.
48. El-Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet. 2007; 99: 236-241.
49. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005; 174: 485-490.